國立虎尾科技大學 |

Non-Alcoholic Fatty Liver Disease = A 360-degree Overview /

Record Type:	Language materials, printed : Monograph/item
Title/Author:	Non-Alcoholic Fatty Liver Disease/ edited by Elisabetta Bugianesi.
Reminder of title:	A 360-degree Overview /
other author:	Bugianesi, Elisabetta.
Description:	X, 362 p. 45 illus., 41 illus. in color.online resource. :
Contained By:	Springer Nature eBook
Subject:	Hepatology. -
Online resource:	https://doi.org/10.1007/978-3-319-95828-6
ISBN:	9783319958286

Non-Alcoholic Fatty Liver Disease = A 360-degree Overview /
Non-Alcoholic Fatty Liver DiseaseA 360-degree Overview /[electronic resource] :edited by Elisabetta Bugianesi. - 1st ed. 2020. - X, 362 p. 45 illus., 41 illus. in color.online resource.

Introduction -- Obesity and NAFLD: same problem? The burden of NAFLD worldwide -- Histo-pathology of NAFLD -- NAFLD and insulin resistance: a multisystemic -- Etiopathogenesis of NAFLD: diet, gut and NASH -- Etiopathogenesis of NAFLD: molecular mechanisms of fibrogenesis -- The natural history of NAFLD: Environmental vs Genetic Risk Factors -- NAFLD and endocrine disease: clinical implications -- NAFLD and Cardiovascular Disease: clinical implications -- NAFLD, Hepatocellular Carcinoma and extrahepatic cancers -- NAFLD in children: implications for the future -- Diagnostic algorithm for the identification of NAFLD in primary care -- Non-Invasive diagnostic approach to NASH: Biological Markers -- Non-Invasive diagnostic approach to NASH: Radiological Diagnostics -- Dietary approach to NAFLD -- Physical Activity in NAFLD: what and how much? Pharmacological Therapy of NASH -- Bariatric Surgery and NASH: a feasible option? Liver transplantation and NASH -- Unmet needs and future goals.

The goal of this book is to promote awareness of non-alcoholic fatty liver disease (NAFLD) – which is rapidly replacing viral hepatitis as the leading cause of chronic liver disease in Europe, North and South America and Asia – and to share the latest information on evolving approaches to diagnosis and treatment. The book offers a comprehensive overview of the current topics of interest in the field, and provides clinical guidance on NAFLD through a multidisciplinary approach based on the latest scientific understanding of this multisystemic disease, involving the expertise of specialists including hepatologists, diabetologists, and cardiologists. The respective contributions address various aspects, including the newly released international guidelines, novel diagnostic modalities, and new experimental drugs. The work will appeal to a broad readership, from residents in internal medicine to specialists.

ISBN: 9783319958286

Standard No.: 10.1007/978-3-319-95828-6doiSubjects--Topical Terms:

673859
Hepatology.

LC Class. No.: RC841-858.P35

Dewey Class. No.: 616.36

Non-Alcoholic Fatty Liver Disease = A 360-degree Overview /
LDR:03214nam a22003855i 4500 001 1029797
003 DE-He213
005 20200928132548.0
007 cr nn 008mamaa
008 210318s2020 gw | s |||| 0|eng d
020 $a 9783319958286 $9 978-3-319-95828-6
024 7 $a 10.1007/978-3-319-95828-6 $2 doi
035 $a 978-3-319-95828-6
050 4 $a RC841-858.P35
072 7 $a MJJ $2 bicssc
072 7 $a MED031000 $2 bisacsh
072 7 $a MJJ $2 thema
082 0 4 $a 616.36 $2 23
245 1 0 $a Non-Alcoholic Fatty Liver Disease $h [electronic resource] : $b A 360-degree Overview / $c edited by Elisabetta Bugianesi.
250 $a 1st ed. 2020.
264 1 $a Cham : $b Springer International Publishing : $b Imprint: Springer, $c 2020.
300 $a X, 362 p. 45 illus., 41 illus. in color. $b online resource.
336 $a text $b txt $2 rdacontent
337 $a computer $b c $2 rdamedia
338 $a online resource $b cr $2 rdacarrier
347 $a text file $b PDF $2 rda
505 0 $a Introduction -- Obesity and NAFLD: same problem? The burden of NAFLD worldwide -- Histo-pathology of NAFLD -- NAFLD and insulin resistance: a multisystemic -- Etiopathogenesis of NAFLD: diet, gut and NASH -- Etiopathogenesis of NAFLD: molecular mechanisms of fibrogenesis -- The natural history of NAFLD: Environmental vs Genetic Risk Factors -- NAFLD and endocrine disease: clinical implications -- NAFLD and Cardiovascular Disease: clinical implications -- NAFLD, Hepatocellular Carcinoma and extrahepatic cancers -- NAFLD in children: implications for the future -- Diagnostic algorithm for the identification of NAFLD in primary care -- Non-Invasive diagnostic approach to NASH: Biological Markers -- Non-Invasive diagnostic approach to NASH: Radiological Diagnostics -- Dietary approach to NAFLD -- Physical Activity in NAFLD: what and how much? Pharmacological Therapy of NASH -- Bariatric Surgery and NASH: a feasible option? Liver transplantation and NASH -- Unmet needs and future goals.
520 $a The goal of this book is to promote awareness of non-alcoholic fatty liver disease (NAFLD) – which is rapidly replacing viral hepatitis as the leading cause of chronic liver disease in Europe, North and South America and Asia – and to share the latest information on evolving approaches to diagnosis and treatment. The book offers a comprehensive overview of the current topics of interest in the field, and provides clinical guidance on NAFLD through a multidisciplinary approach based on the latest scientific understanding of this multisystemic disease, involving the expertise of specialists including hepatologists, diabetologists, and cardiologists. The respective contributions address various aspects, including the newly released international guidelines, novel diagnostic modalities, and new experimental drugs. The work will appeal to a broad readership, from residents in internal medicine to specialists.
650 0 $a Hepatology. $3 673859
650 0 $a Endocrinology . $3 1254221
650 0 $a Cardiology. $3 593957
650 2 4 $a Endocrinology. $3 645497
700 1 $a Bugianesi, Elisabetta. $e editor. $4 edt $4 http://id.loc.gov/vocabulary/relators/edt $3 1326613
710 2 $a SpringerLink (Online service) $3 593884
773 0 $t Springer Nature eBook
776 0 8 $i Printed edition: $z 9783319958279
776 0 8 $i Printed edition: $z 9783319958293
856 4 0 $u https://doi.org/10.1007/978-3-319-95828-6
912 $a ZDB-2-SME
912 $a ZDB-2-SXM
950 $a Medicine (SpringerNature-11650)
950 $a Medicine (R0) (SpringerNature-43714)